ChromaDex News

Roth MKM: Maintains ChromaDEX (CDXC.US) rating, adjusted from buy to buy rating, and adjusted target price from $4.25 to $6.00.

Zhitong FinanceApr 9 22:02

ChromaDex Analyst Ratings

BenzingaApr 9 21:57

Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6

BenzingaApr 9 21:59

ChromaDex Analyst Ratings

BenzingaMar 11 19:21

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6

BenzingaMar 11 19:23

Chromadex's Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating: An Analysis of Jeffrey Cohen's Recommendations

TipRanksNov 10, 2023 01:19

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Chromadex (CDXC) and Glaukos (GKOS)

TipRanksNov 9, 2023 20:22

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $5 Price Target

BenzingaAug 10, 2023 19:50

ChromaDex Analyst Ratings

BenzingaAug 10, 2023 19:49

H.C. Wainwright Sticks to Its Buy Rating for Chromadex (CDXC)

TipRanksAug 10, 2023 18:35

H.C. Wainwright Keeps Their Buy Rating on Chromadex (CDXC)

TipRanksJun 5, 2023 18:25

HC Wainwright Adjusts Price Target on ChromaDex to $5 From $5.50, Keeps Buy Rating

MT NewswiresMar 13, 2023 19:36

B. Riley Trims ChromaDex's Price Target to $2 From $2.10 After Mixed Q4 Metrics, Keeps Neutral Rating

MT NewswiresMar 9, 2023 21:15

ChromaDex Analyst Ratings

Benzinga Analyst RatingsFeb 1, 2023 19:11

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $5.5 Price Target

Benzinga Real-time NewsFeb 1, 2023 19:11

H.C. Wainwright Reaffirms Their Buy Rating on Chromadex (CDXC)

TipRanksNov 14, 2022 19:40